Alkem Laboratories Q1 FY27: Profit Falls 22%, Revenue Up 11%

Results snapshot for the June 2026 quarter

Alkem Laboratories Ltd. reported its financial results for the quarter ended June 30, 2026 (Q1 FY27), showing steady revenue growth but a sharp decline in profit. Consolidated revenue from operations rose to ₹3,740 crore, compared with ₹3,371 crore a year earlier. Consolidated net profit was reported at ₹520 crore, down from ₹664 crore in the same quarter last year, implying a year-on-year decline of about 21%-22%. Operating performance improved in absolute terms, but margins moved lower. The numbers placed focus on how cost lines and taxes shaped the quarter’s bottom line. The company also issued an unaudited results filing with detailed consolidated and standalone line items for the same period.

Revenue rose, but profitability contracted

Revenue growth was led by a higher sales base across India and international markets, as reflected in the company’s segment disclosures. Consolidated EBITDA increased to ₹766 crore from ₹739 crore in the year-ago quarter, indicating a 3.7%-4% rise. Even with EBITDA growth, the EBITDA margin contracted to 20.48%-20.5% from 21.92%-21.9% last year. That margin compression stood out because it came in a quarter when revenue expanded by about 10.9%-11%. The company’s R&D expense for Q1 FY27 was ₹150 crore, which it stated was 4% of revenue from operations. This R&D ratio provides a clear reference point for the quarter’s investment in product development relative to sales.

Tax line and other reported metrics

A results summary in the provided data also highlighted a sharp rise in tax expense to ₹251 crore compared with ₹103 crore a year ago. Separately, Alkem’s consolidated filing (for the quarter ended June 30, 2026) reported profit before tax of ₹422.85 crore and tax expense of ₹171.17 crore. The same filing reported “profit for the period” at ₹251.11 crore, along with total comprehensive income of ₹366.38 crore. These line items are presented as disclosed in the results text shared, even as other reports in the same compilation cite consolidated net profit of ₹520 crore. The consolidated filing also disclosed basic and diluted earnings per share at ₹19.77 for the quarter.

India and international sales: what moved in Q1

On the sales mix, the data indicates India sales rose 10.3% to ₹2,498 crore, while international sales were ₹1,222 crore, up 16% year on year. Within international markets, US sales were ₹744 crore in Q1 FY27, growing 6.5% year on year. Non-US sales increased much faster, rising 34.5% to ₹478.5 crore. Non-US sales contribution to total sales increased to 12.9% from 10.8% in Q1 FY26, based on the disclosed comparison. Taken together, the regional split suggests growth outside the US accelerated more strongly than US growth during the quarter.

Consolidated versus standalone: what the filing shows

In the unaudited consolidated results for the quarter ended June 30, 2026, Alkem reported revenue from operations of ₹3,740.15 crore and total income of ₹3,892.90 crore. Total expenses for the consolidated results were ₹3,120.91 crore, as per the filing details provided. For standalone results, revenue from operations was reported at ₹2,667.73 crore and total income at ₹2,804.35 crore. Standalone total expenses were ₹2,005.93 crore, and profit before tax from continuing operations was ₹798.42 crore. The standalone filing also reported tax expense of ₹228.44 crore and profit for the period from continuing operations of ₹569.98 crore. These consolidated and standalone disclosures help readers map performance at the group level versus the India-listed entity’s standalone operations.

Capex decision: Baddi manufacturing block

Alongside the quarterly performance, the company approved an investment of up to ₹75 crore for a new manufacturing block at Baddi. The disclosure was referenced in the same set of Q1 results updates. While the text provided does not include commissioning timelines or capacity details, the size of the approved capex is a concrete datapoint for investors tracking manufacturing expansion. For a pharma company, such facility investments can be relevant for future product launches and supply readiness. The approval also signals that management is committing capital even as quarterly margins softened.

Stock reaction and scheduled investor communication

Following the earnings, Alkem Laboratories shares were trading at ₹5,300 on the NSE, down 2.74% at the time noted in the report. The company also scheduled a conference call on August 14, 2026, to discuss Q1 FY27 results. Managing Director Sandeep Singh and CFO Nitin Agrawal were listed to lead the discussion, hosted by Motilal Oswal Securities Ltd. The call was scheduled from 4:30 PM to 5:30 PM IST. Dial-in details for India were provided as +91 22 6280 1149 and +91 22 7115 8050. The company had also declared a dividend of ₹10.00 on August 7, 2026, as stated in the data.

Key numbers table

All monetary figures below are shown in ₹ crore (₹ million figures converted to ₹ crore where applicable).

What investors tracked in this quarter

The quarter set up a clear contrast between revenue growth and profit decline, with margins contracting despite higher EBITDA in absolute terms. Investors also had multiple tax and profit line references in the shared disclosures, including a results summary that flagged higher tax expense year on year. The regional sales data showed India growing in double digits and international markets accelerating, particularly outside the US. R&D spending was explicitly quantified both in rupee terms and as a percentage of revenue, which makes it easier to compare with future quarters. The Baddi capex approval adds a forward operational datapoint, although the provided text does not detail timelines. Near term, the scheduled conference call was positioned as the main forum for management to address drivers of margin movement and regional growth performance.

Conclusion

Alkem’s Q1 FY27 results delivered about 11% revenue growth to ₹3,740 crore, while consolidated net profit was reported at ₹520 crore, down around 22% year on year. EBITDA rose to ₹766 crore but margins fell to about 20.5%. The quarter also featured ₹150 crore of R&D spend and an approved capex of up to ₹75 crore for a new Baddi manufacturing block. Management’s next detailed commentary was scheduled for the August 14, 2026 conference call, where investors typically look for clarity on cost trends, taxes, and the sustainability of regional growth.